RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Phase 1

Repligen Corporation